Related references
Note: Only part of the references are listed.Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus
Catherine Sheffield et al.
Endocrine Practice (2013)
Diabetes drug pioglitazone (Actos): risk of fracture
Reza Heidarpour Meymeh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2007)
Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus
Shari Bolen et al.
ANNALS OF INTERNAL MEDICINE (2007)
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
SH Simpson et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Hepatotoxicity associated with acarbose therapy
SH Hsiao et al.
ANNALS OF PHARMACOTHERAPY (2006)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
RJ Heine et al.
ANNALS OF INTERNAL MEDICINE (2005)
Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy
LD May et al.
ANNALS OF INTERNAL MEDICINE (2002)
Hepatocellular injury in a patient receiving pioglitazone
K Maeda
ANNALS OF INTERNAL MEDICINE (2001)
Hepatocellular injury in a patient receiving rosiglitazone. A case report (vol 132, pg 121, 2000)
J Al-Salman
ANNALS OF INTERNAL MEDICINE (2000)
Hepatocellular injury in a patient receiving rosiglitazone - A case report
J Al-Salman et al.
ANNALS OF INTERNAL MEDICINE (2000)
Hepatic failure in a patient taking rosiglitazone
LM Forman et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
